false
OasisLMS
zh-CN,zh-TW,en,fr,de,hi,ja,ko,pt,es
Login
Catalog
Precocious Puberty: A Clinical Practice Guideline ...
Guideline: Central Precocious Puberty
Guideline: Central Precocious Puberty
Back to course
Pdf Summary
This Endocrine Society guideline updates the diagnosis and treatment of central precocious puberty (CPP), defined traditionally as puberty before age 8 in girls and 9 in boys. CPP results from early activation of the hypothalamic-pituitary-gonadal axis and may affect adult height, psychosocial well-being, and long-term health.<br /><br />Using GRADE-based evidence review, the panel issued 10 conditional recommendations:<br /><br />- For girls with breast development (Tanner B2) at ages 7.0–8.0 years, the panel suggests watchful waiting with exams every 4–6 months rather than immediate testing.<br />- For girls younger than 7 with initial B2, a 4–6 month observation period is suggested to distinguish slowly progressive from rapidly progressive puberty.<br />- If testing is needed, start with an ultrasensitive basal LH test rather than immediate GnRH/GnRHa stimulation testing.<br />- Routine brain MRI is not recommended for girls age 6.0–8.0 years or boys age 8.0–9.0 years without CNS symptoms.<br />- Routine genetic testing is discouraged, though it may be considered in familial CPP through shared decision-making.<br />- GnRH agonist treatment is suggested for many children with CPP, but not all subgroups clearly benefit, especially older girls with slowly progressive disease or children already near peak growth.<br />- If long-acting GnRH agonists will be used long term, treatment should start with the long-acting formulation rather than monthly injections.<br />- Routine biochemical monitoring during treatment is discouraged; clinical monitoring is preferred unless treatment failure is suspected.<br />- Routine addition of growth hormone is not recommended.<br />- GnRH agonists should not routinely be continued beyond about age 10–11 in girls or 11–12 in boys, or corresponding bone ages.<br /><br />Overall, the guideline emphasizes individualized care, shared decision-making, lower-cost and lower-burden evaluation strategies, and more selective use of imaging, genetic testing, and adjunct therapies. It also highlights major evidence gaps, especially for boys and for long-term outcomes.
Keywords
central precocious puberty
Endocrine Society guideline
GnRH agonist therapy
hypothalamic-pituitary-gonadal axis
watchful waiting
basal LH testing
brain MRI
genetic testing
shared decision-making
puberty diagnosis
×
Please select your language
1
English